BioMarin Pharmaceutical Inc.
BMRN
Rang în acțiuni
#1982
BioMarin Pharmaceutical Inc. specializes in creating and bringing to market... BioMarin Pharmaceutical Inc. specializes in creating and bringing to market treatments for individuals suffering from severe and often fatal rare disorders and other critical medical conditions. The company currently markets several key pharmaceutical products. Among these are Vimizim, an enzyme replacement therapy targeting mucopolysaccharidosis (MPS) IV type A, a specific lysosomal storage disorder, and Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for individuals with MPS VI. Another notable offering is Kuvan, a unique synthetic oral version of 6R-BH4, prescribed for phenylketonuria (PKU), an inherited metabolic condition. Further expanding its product portfolio, BioMarin provides Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme administered via subcutaneous injection to lower blood Phe levels. Also available are Brineura, a recombinant human tripeptidyl peptidase 1 used in treating ceroid lipofuscinosis type 2, a variant of Batten disease; Voxzogo, a daily injectable c-type natriuretic peptide analog for achondroplasia; and Aldurazyme, a refined protein mirroring the naturally occurring human enzyme alpha-L-iduronidase. Beyond its established products, BioMarin has a robust development pipeline. This includes valoctocogene roxaparvovec, an adeno-associated virus vector undergoing Phase III clinical trials for severe hemophilia A. Additionally, BMN 307, an AAV5-mediated gene therapy, is in Phase 1/2 trials, aiming to normalize blood phenylalanine levels in PKU patients, while BMN 255 is also in Phase 1/2 trials for primary hyperoxaluria. Its clientele spans specialty pharmacies, hospitals, international government health bodies, and a network of distributors and pharmaceutical wholesalers. These services reach patients and healthcare providers across the United States, Europe, Latin America, and other global markets. BioMarin maintains strategic licensing and collaborative alliances with partners such as Sarepta Therapeutics, Ares Trading S.A., Catalyst Pharmaceutical Partners, Inc., and Asubio Pharma Co., Ltd. Established in 1996, the company's corporate headquarters are located in San Rafael, California.
Preț acțiune
$54.55
Ultima sincronizare: 2026-10-16
Capitalizare de piață
$10.56B
Schimbare (1 zi)
-2.68%
Schimbare (1 an)
-21.72%
Țară
US
Tranzacționează BioMarin Pharmaceutical Inc. (BMRN)
Categorie
Healthcare
Capitalizarea de piață a BioMarin Pharmaceutical Inc.(BMRN)
Capitalizare de piață: $10.56B
În anul October 2026, BioMarin Pharmaceutical Inc. are o capitalizare de piață de $10.56B. Acest lucru face ca BioMarin Pharmaceutical Inc. să fie a 1982nd-a cea mai valoroasă companie din lume, conform datelor noastre. Capitalizarea bursieră reprezintă valoarea totală de piață a acțiunilor în circulație ale unei companii listate și este utilizată frecvent pentru a măsura valoarea unei companii.
Istoricul capitalizării de piață a BioMarin Pharmaceutical Inc. din 2015 până în 2026
BMRN în comparație cu top 5 cele mai populare stocks
